Ewing sarcoma (ES), an aggressive bone and soft-tissue tumor, is treated with chemotherapy, radiotherapy, and surgery. Intra-operative distinction between healthy and tumorous tissue is of paramount importance but challenging, especially after chemotherapy and at complex anatomical locations. Near infrared (NIR) fluorescenceguided surgery (FGS) is able to facilitate the determination of tumor boundaries intraoperatively, improving complete resection and therefore survival. This review evaluates potential ES-specific proteins from the literature as targets for NIR FGS. 
| INTRODUCTION
Ewing sarcoma (ES) is a small, round cell sarcoma that shows pathognomonic molecular findings, and varying degrees of neural differentiation. 1 ES is the second most common primary osseous malignancy in children and young adults after osteosarcoma, with a peak incidence in the second decade of life. [2] [3] [4] Treatment generally consists of chemotherapy followed by surgery and/or radiotherapy. This multimodal approach drastically improved survival, from a 10-year overall survival of approximately 10% up to 55% to 65% in patients with localized disease and 20% to 35% for patients with metastatic disease. [5] [6] [7] [8] [9] [10] During the last few decades local treatment has changed from routinely amputation to limb-salvage, in which preservation of a functioning limb is at the essence of achieving clear margins. 7 ES arises from the diaphysis of long bones with early involvement of the surrounding soft tissue. The soft tissue mass is usually large, circumferential around the involved bone and might even exceed the intra-osseous component in size. 1 Neoadjuvant treatment causes shrinkage of both the bony and soft tissue component, but tumor boundaries can still consist of vital tumor cells. The infiltrative rather than pushing type of tumor outgrowth of ES impedes border definition, but achieving wide surgical resection is of paramount importance for survival in ES. Incomplete resection occurs in 20% to 30% of the cases. [11] [12] [13] A large study of 244 patients registered in the Cooperative Ewingʼs Sarcoma Studies showed that the local recurrence rate in patients with or without systemic metastasis was significantly lower after wide resection compared to marginal or intralesional resection (5% vs 12%). 13 Another large study of 512 ES patients showed that local control and 5-year disease-free survival are significantly better when adequate surgical margins are achieved (96.6% vs 71.7% and 69.6% vs 46.3% respectively). 12 Developments in intra-operative imaging, like computer tomography-based systems, make accurate defining and localization of the osseous margins possible. Magnetic resonance imaging enables neoadjuvant treatment. 7, 14, 15 During surgery the surgeon relies mostly on his eyes and hands when distinguishing tumor issue margins.
Furthermore, about 50% of the Ewing sarcoma's arise in the axial skeleton with the pelvic and spine as common locations. Accurate surgery with clear margins is challenging in these complex anatomical locations. 5 This emphasizes the need for tools to define surgical margins of soft tissue involvement during surgery. The aim of this study was to provide an overview of possible tumor-specific biomarkers in ES. For this purpose, a systematic analysis of scientific literature was conducted, using the recently published ES surfaceome database, based on three ES cell lines (A673, TC-32, and TTC-466) as a reference. 26 
| MATERIALS AND METHODS
This study was performed according to the Preferred Reporting
Items for Systematic Reviews and Meta-analyses guidelines. 27 The review protocol for this study was prospectively registered at PROSPERO* (registration number CRD42017080720).
| Search strategy
A search strategy was developed, and searches were run in the following databases in October 2017: PubMed, Embase, Cochrane Library, Academic Search Premier and Web of Science. Search strategies for all databases were adapted from the PubMed strategy.
The search strategy consisted of the keywords "Ewing sarcoma,"
"biomarker," "target" and abbreviations thereof. See Supporting Information file 1 for the complete search strategies for each database.
| Eligibility criteria
Multiple study designs were considered for this review, including clinical trials (phase I, II, and III) and prospective or retrospective cohort studies. Animal studies, case reports, reviews, viewpoints, or conference reports were excluded. We searched for systematic reviews on this topic and only included original articles in our review.
Studies were eligible for inclusion if they met the following criteria:
(1) Report of cell surface protein expression in the primary ES tumor; 
| Data extraction
The following data were extracted from eligible studies: target characteristics, sample size, type of sample, percentage of positive ES samples and pattern of expression.
| Target selection: scoring system
Considerations to select the optimal target for tumor imaging are: (1) The location and accessibility of the target on the cell membrane; (2) Upregulation on tumor cells compared to cells in adjacent normal tissue. Note that targets/biomarkers like FLI1 and NKX2.2, which are considered standards for ES in diagnostics and pathology, cannot be used for in vivo imaging, because of nuclear or cytoplasmic expression. [28] [29] [30] [31] [32] To select the best biomarkers useful for NIR FGS in ES, we developed a scoring system based on the Target Selection Criteria BOSMA ET AL.
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characteristics and the evidence from the literature search ( Table 1 ).
The scoring system is based on five domains: indicates that a target is suitable for imaging purposes.
The maximum score for a target is 10 points. We chose 7 points as the cut-off value for potentially suitable targets for targeted imaging in ES.
3 | RESULTS
| Study selection
The initial search strategy identified 4943 records (PubMed n = 2203;
Embase n = 1585; Web of Science n = 1054; Cochrane Library n = 19;
Academic Search Premier n = 82). studies were not about cell surface expression in ES, two studies were not about expression in primary ES tumors and of one study no full text was available. In total 86 studies were included studying 47 biomarkers ( Figure 1 ). The reviewers initially disagreed on 21 inclusions during the selection process, but eventually a consensus was reached for all studies.
| Study characteristics
The characteristics of the 47 included biomarkers are presented in Supporting Information file 2.
| Candidate proteins for targeted imaging
The target scoring system (Table 1 ) was applied to the 47 targets listed in appendix II. Nine targets scored seven points or higher. The expression level is much higher in ES compared with MSC. 33 A preclinical study using 64 Cu labeled mouse monoclonal antibody against CD99 detected primary ES tumors and metastases with higher sensitivity than conventional FDG-PET in vitro as well as in xenograft mouse models. 35 Based on this study CD99-targeted FGS seems feasible, preferably using human or humanized antibodies to avoid human anti-mouse induced complications. Human CD99 antibody scFvfragments have recently been developed using a synthetic phage antibody library. 36 Although intended for therapy, the specificity of 
LINGO1
Leucine-rich repeat and immunoglobulin domain containing protein 1 (LINGO1) is a functional component of the Nogo receptor. It plays a key role in the central nervous system where it is an important negative regulator of oligodendrocyte differentiation and axonal myelination. 44, 45 It is characterized by a large and well defined extracellular domain. 46 Town et al 33 explored the cell surface proteome of ES and found that LINGO1 is highly expressed in 91% of ES and not in any other somatic tissue apart from the brain, suggesting it as an appropriate candidate for imaging. The human monoclonal antibody Opicinumab (Li81, BIIB033), has recently been developed to block LINGO1 as a treatment of multiple sclerosis. Li81 was isolated using Fab phage display technology and engineered into a human IgG1 mono-clonal lonal antibody with high affinity and specificity to LINGO1. 47, 48 Initial clinical trials showed disappointing results, but regardless of its therapeutic efficiency this monoclonal antibody could in principle be applied for use of FGS in ES.
IGF-1R
Insulin 
10

CXCR4
Receptor for chemokine SDF-1/CXCL12, which is involved in chemotaxis of hematopoietic cells and neuron generation. In cancer is plays a role in the tumor microenvironment, where it is associated with metastasis, angiogenesis and tumor growth.
9
NPY-R-Y1 Expressed in the central nerve system and periphery (heart, kidney, gastro-intestinal tract); activation is associated with modulation of the MAPK pathway, which leads to increased or uncontrolled cell proliferation and resistance to apoptosis. 
IGF-1R
A tyrosine kinase receptor (TKR) that is activated by insulin-like growth factor 1 (IGF-1) and involved in hypertrophy of skeletal muscles and other tissues and cell survival; shows antiapoptotic effects that allow cancer cells to resist the cytotoxic properties of chemotherapeutic drugs or radiotherapy. NOTCH-R Involved in cell signaling; shows oncogenetic (suppress apoptosis; promote neo-angiogenesis, tumor cell growth and metastasis) and tumor-suppressive (inhibit angiogenesis and induced cell differentiation or apoptosis) functions.
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CAM/anchoring proteins
Occludin Integral plasma-membrane protein that is required for cytokine-induced regulation and formation of the tight junction paracellular permeability barrier; in cancer it attributes to increased invasion and reduced adhesion which promotes metastasis.
9
Claudin-1 Tight junction protein that contributes in cell-to-cell adhesion by forming continuous seals around cells; dysregulation of claudins plays a role in tumorigenesis, the exact underlying mechanism remains unclear. and progression. 58 C-kit is expressed by the KIT gene which is highly upregulated in ES cell-lines. 33 The intensity of the expression varies however and only 60% of ES show a strong membranous expression (range 31% to 100%). Staining intensity varies from weak to strong and is diffuse membranous and/or cytoplasmic. 59 Metildi et al 60 Although potential therapeutic antibodies like bronctictuzumab against activated NOTCH1 are being evaluated for therapy in patient-derived xenografts. Direct imaging of NOTCH has not been described yet.
| CAMs or anchoring proteins
CAMs are membrane-bound proteins that affect cellular processes.
Generally 
Occludin
Occludin is an integral plasma-membrane protein that is required for cytokine-induced regulation and formation of the tight junction paracellular permeability barrier. Occludin is able to induce adhesion when cells lack tight junctions. 67 Although OCLN, the gene encoding occludin is often downregulated in cancers. It is highly upregulated in ES. 33 The scoring system used in this review is a guidance tool that helped in selecting potential targets. We chose a score of 7 as the cut-off point to identify potential targets. Other factors play a role in selecting the most optimal candidate, such as toxicity of an antibody, the availability of a humanized antibody and results from previous studies.
Following this study, immunohistochemical analysis and cell linebased validation of the potential biomarkers should be performed.
Next, imaging of a peptide or an antibody (derivative) conjugated to a fluorophore should be assessed in vitro. Finally, if a target still shows potential, in vivo testing with a specific binding ligand in a tumor mouse model is needed.
| CONCLUSION
In ES a large number of tumor-specific biomarkers is upregulated.
With the use of a scoring system, we identified CD99, LINGO-1, C-kit, NOTCH receptor, CxCR4, NPY receptor Y1, Claudin-1 and
Occludin as the most interesting ES specific biomarkers for the use in NIR fluorescence guided surgery. Further immunohistochemical and cell line-based research of these potential targets should be performed to elucidate the most optimal candidate.
With this study, the first steps are made to explore this promising technique that is on the doorstep of optimizing orthopedic oncologic surgery.
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